It was a great pleasure to meet with Michael Oshinsky (National Institute for Neurological Disorders and Stroke, NINDS/NIH, Bethesda, MD, USA) to discuss the NIH Roadmap for Migraine Research.
The ‘NIH Roadmap for Migraine Research Update’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- Could you give us a brief overview of the NIH roadmap for migraine research and its aims?
- What updates have been added to the roadmap?
- What are the most important priorities in migraine research for the coming year?
- What are your take home messages?
Disclosures: Michael Oshinsky discloses that he is a US Federal Employee.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of the AHS Virtual Annual Scientific Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!